A Mab A Case Study In Bioprocess Development

| Parameter | Lab (2 L) | Pilot (50 L) | Commercial (2,000 L) | |-----------|-----------|--------------|----------------------| | Temp (°C) | 37 → 33 (shift) | Same | Same | | pH | 7.0 → 6.9 (shift) | Same | Same | | DO (%) | 40 | 40 | 40 | | Agitation (tip speed) | 0.3 m/s | 0.35 m/s | 0.45 m/s | | Sparger type | Microsparger | Microsparger | Ring + micro |

Analyzed via Size Exclusion Chromatography (SEC-HPLC). Glycan Profile: Monitored to ensure consistent efficacy. 4.2. Identifying and Characterizing Product Variants

The 2,000L harvest contained A Mab at 6.8 g/L, plus host cell proteins (HCPs), DNA, and cell debris. The train: A Mab A Case Study In Bioprocess Development

Despite high affinity capture, the Protein A eluate contained high molecular weight (HMW) aggregates (

This public link is valid for 7 days and shares a thread, including any personal information you added. This link or copies made by others cannot be deleted. If you share with third parties, their policies apply. Can’t copy the link right now. Try again later. | Parameter | Lab (2 L) | Pilot

A Mab’s unique CDR regions caused a conformational shift at low pH. The team screened over 12 elution buffers and found that adding 0.5 M arginine and 50 mM sodium acetate at pH 3.8, followed by immediate neutralization to pH 5.0, reduced aggregates to 2.5%.

Using prior knowledge and failure mode effects analysis (FMEA) to identify process parameters that most significantly affect CQAs. If you share with third parties, their policies apply

Rather than treating Chemistry, Manufacturing, and Controls (CMC) as a rigid, check-the-box regulatory exercise, the A-Mab study acts as an instructional framework. It demonstrates how enhanced product and process understanding can build safety, efficacy, and quality directly into a biologic’s lifecycle. 1. The Core Philosophy: Quality by Design (QbD)

, protecting downstream chromatography columns from fouling. Capture Step: Protein A Chromatography

Loading was set to 85% of the manufacturer's suggested dynamic binding capacity to ensure high recovery. This step routinely achieved >95% purity. 3.3. Polishing Steps: Ion Exchange Chromatography

Monoclonal antibodies (mAbs) have become indispensable weapons in the arsenal against cancer, autoimmune diseases, and other chronic conditions. The journey from laboratory discovery to a final, approved drug product is a complex and costly undertaking, heavily reliant on efficient bioprocess development. As the demand for these targeted therapies rises, the industry faces immense pressure to optimize production workflows, reduce costs, and accelerate timelines. This article explores the multifaceted world of mAb bioprocess development through the lens of case studies, offering a practical roadmap from upstream cell culture to commercial manufacturing.